David Carr Locke, MD
Gastroenterology · New York, NYNPI 1417913609
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $1,959,305 of the $2,011,634 with a category attached, or 97.4%. US Endoscopy accounts for 97.6% of it on its own, with 26 other manufacturers making up the rest. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $7951.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Endoscopy$2M
- Boston Scientific$38K
- Steris Corporation$3K
- W. L. Gore & Associates, Inc.$2K
- Conmed Corporation$972
- Olympus America Inc.$644
- plus $4K from 21 others
Across 14 payments — averaging $8933.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$125K
What the payments were for
- Royalty or licence$1,959,30597%
- Consulting fees$20,4751%
- Speaking & faculty fees$11,3751%
- Grants$5000%
- Travel & lodging$7,4240%
- Food & beverage$12,5221%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Endoscopy | 28 | $1,962,905 |
| Boston Scientific | 130 | $38,259 |
| Steris Corporation | 6 | $2,557 |
| W. L. Gore & Associates, Inc. | 5 | $2,404 |
| Conmed Corporation | 9 | $972 |
| Olympus America Inc. | 11 | $644 |
| AbbVie | 13 | $551 |
| Medtronic | 4 | $424 |
| Mauna Kea Technologies, Inc. | 2 | $355 |
| Galvanize Therapeutics, Inc | 3 | $307 |
| Micro-tech Endoscopy USA, Inc. | 2 | $278 |
| Cook Medical LLC | 1 | $265 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $229 |
| Fujifilm Healthcare Americas Corporation | 1 | $215 |
| Johnson & Johnson | 7 | $211 |
| Covidien LP | 3 | $211 |
| Endogastric Solutions, Inc | 3 | $180 |
| Lumendi LLC | 1 | $154 |
| Merit Medical Systems Inc | 1 | $129 |
| QOL Medical, LLC | 1 | $125 |
| Celltrion USA Inc. | 2 | $76 |
| Bristol Myers Squibb | 2 | $64 |
| Pentax Of America, Inc. | 1 | $36 |
| Merck | 1 | $24 |
| Amgen | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NA$1,409,020
- Carr-Locke Injection Needle$550,286
- RESOLUTION CLIP$13,707
- GENERAL HEMOSTASIS$5,666
- GENERAL - THERAPIES$3,278
- EXALT Model D$3,271
- VIABIL Biliary Endoprosthesis$2,289
- GENERAL - BILIARY DEVICES$2,238
- WALLFLEX$2,234
- SPYGLASS$1,779
- SPYBITE$850
- CONMED BILIARY$575
- APOLLO ESG System$469
- GI Genius$297
- ALIYA SYSTEM$280
- EchoTip$265
- EXALT$239
- FUJIFILM$215
- AXIOS$174
- SureClip and Traction Device$170
How this compares
$2,011,634 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 14 | $27,498 |
| LinzessLinaclotide | 18 | $12,227 |
| Omeprazole | 122 | $2,317 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 59 | $888 |
| Esomeprazole Magnesium | 30 | $722 |
| Sucralfate | 11 | $707 |
| Pantoprazole Sodium | 49 | $592 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 11 | $511 |
| Famotidine | 25 | $410 |
| Lansoprazole | 13 | $359 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 17 | $253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $551 | $39,72432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New York
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
- Ilan WeisbergNew York$446K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.